<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201230049889N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-08-14</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Time-Restricted Eating on Arterial Stiffness Indices in Patients with Metabolic Syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Time-Restricted Eating versus Standard Dietary Advice on Arterial Stiffness Indices in Men with Metabolic Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64485</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization method: simple
Randomization Unit: Individual
Randomization tool: sealed envelope  
(SNOSE: sequentially numbered, opaque, sealed envelopes)
How to make a random sequence: Randomaize.com randomization site
Explanation about allocation concealment: Random numbers are prepared with the help of Randomaize.com and printed and placed inside the envelope by a member of the research team. The lid of the envelopes will be closed and its contents will not be visible from the outside. Then first, the purpose of the study is explained to the person who meets the listed conditions. If desired, the person signs the informed consent form and takes an envelope. Then opens it and based on the contents of the envelope, the person is entered in the intervention or control group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Metabolic syndrome. Condition 2: Arterial stiffness indices. Condition 3: Time-restricted eating.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, people will receive food in a period of 10 hours. It is recommended that this period be between 6 am and 8 pm. All foods and drinks except water, tea and coffee without added sweeteners should be consumed during this period. Due to not affecting the quality of sleep, tea and coffee consumption is allowed before 8 pm. With the help of researchers, participants will choose the best time frame that fits their life schedule. The patients' diet is according to their taste and freely, and there are no food restrictions. Participants will be explained about a healthy diet based on national dietary recommendations. Intervention 2: Control group: The control group will have a diet without time restriction and will receive the necessary recommendations about a healthy diet based on national dietary guidelines. In this group, the diet of the patients is according to their taste and freely, and there are no food restrictions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Persian cohort center will provide the data to researchers in a case-by-case basis and the center has the complete ownership of the data.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Aliyeh Ghannadzadeh Yazdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nutrition Department, School of Medicine, East door of Ferdowsi University, Azadi Sq.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177948564</zip>
        <telephone>+98 51 3882 7034</telephone>
        <email>GhannadzadehYA981@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohsen Nemati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nutrition Department, School of Medicine, East door of Ferdowsi University, Azadi Sq.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177948564</zip>
        <telephone>+98 51 3882 7034</telephone>
        <email>NematyM@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Men between the ages of 18 and 65
Body mass index (BMI) below 35
Diagnosis of metabolic syndrome according to the International Diabetes Federation (IDF) definition
Willingness to participate in the study by signing the informed consent form</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Diabetes
Thyroid disorders based on thyroid tests or thyroxine use
Eating disorders
Serious diseases that affect food intake, such as cancer
Using supplements that contain compounds other than vitamins and minerals
Inability to follow time-restricted eating diet
Specific work and sleep schedule
The duration of receiving daily food less than 14 hours</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E88.81</hc_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Metabolic syndrome</hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, people will receive food in a period of 10 hours. It is recommended that this period be between 6 am and 8 pm. All foods and drinks except water, tea and coffee without added sweeteners should be consumed during this period. Due to not affecting the quality of sleep, tea and coffee consumption is allowed before 8 pm. With the help of researchers, participants will choose the best time frame that fits their life schedule. The patients' diet is according to their taste and freely, and there are no food restrictions. Participants will be explained about a healthy diet based on national dietary recommendations.</i_keyword>
      <i_keyword>Control group: The control group will have a diet without time restriction and will receive the necessary recommendations about a healthy diet based on national dietary guidelines. In this group, the diet of the patients is according to their taste and freely, and there are no food restrictions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pulse wave velocity (PWV). Timepoint: At the beginning of the study and after 6 weeks from the start of the study. Method of measurement: Pulse Wave Velocity device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body weight. Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: Scales.</sec_outcome>
      <sec_outcome>Waist circumference. Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Meter.</sec_outcome>
      <sec_outcome>Body composition. Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Bioelectric Impedance Analysis (BIA) device.</sec_outcome>
      <sec_outcome>Complete blood count (CBC). Timepoint: At the beginning of the study (fasting and 120 minutes after a meal) and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Alanine transaminase (ALT). Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Aspartate transaminase (AST). Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>C-Reactive Protein (CRP). Timepoint: At the beginning of the study (fasting and 120 minutes after a meal) and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Total cholesterol. Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Triglyceride. Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>High-density lipoprotein (HDL). Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Low-density lipoprotein (LDL). Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Blood glucose. Timepoint: At the beginning of the study (fasting, 60 minutes after and 120 minutes after a meal) and 3 weeks and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Insulin. Timepoint: At the beginning of the study (fasting, 60 minutes after and 120 minutes after a meal) and 3 weeks and 6 weeks after the start of the study. Method of measurement: Biochemical analysis of blood sample.</sec_outcome>
      <sec_outcome>Insulin resistance. Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: Calculation of Homeostatic Model Assessment (HOMA).</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: Sphygmomanometer.</sec_outcome>
      <sec_outcome>Metabolic rate. Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Indirect calorimetry.</sec_outcome>
      <sec_outcome>Appetite status. Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Visual Analog Scale (VAS).</sec_outcome>
      <sec_outcome>Physical activity. Timepoint: 3 days at the beginning of the study and 3 days at the end of the study. Method of measurement: Pedometer.</sec_outcome>
      <sec_outcome>Sleep status. Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Pitssburg Questionnaire.</sec_outcome>
      <sec_outcome>Quality of life. Timepoint: At the beginning of the study and 6 weeks after the start of the study. Method of measurement: Short form of World Health Organization quality of life questionnaire (WHOQOL-BREF).</sec_outcome>
      <sec_outcome>Dietary intake. Timepoint: At the beginning of the study and 3 weeks and 6 weeks after the start of the study. Method of measurement: 3-day 24-hour recall.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-31</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>School of Medicine, Mashhad University of Medical Sciences, East door of Ferdowsi University, Azadi Sq. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
